Almaaytah A. (2020). Budget Impact Analysis of Switching to Rituximab’s Biosimilar in Rheumatology and Cancer in 13 Countries Within the Middle East and North Africa. Dove Medical Press.
Chicago Style (17th ed.) CitationAlmaaytah A. Budget Impact Analysis of Switching to Rituximab’s Biosimilar in Rheumatology and Cancer in 13 Countries Within the Middle East and North Africa. Dove Medical Press, 2020.
MLA (9th ed.) CitationAlmaaytah A. Budget Impact Analysis of Switching to Rituximab’s Biosimilar in Rheumatology and Cancer in 13 Countries Within the Middle East and North Africa. Dove Medical Press, 2020.
Warning: These citations may not always be 100% accurate.